Moreover, real-world evidence derived from the US Collaborative Network of TriNetX, which analyzed data from individuals with T2DM aged ≥18 years who initiated tirzepatide or a GLP-1 RA between June 1, 2022, and June 30, 2023, suggests that tirzepatide reduces the risk of all-cause mortality by 42%, MACE by 20%, and major adverse kidney events by 46% [84]. This evidence concerns the gene GCG and type 2 diabetes mellitus.